BioPharmSignal logoBioPharmSignal

Biotech News

Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sagimet Biosciences (SGMT)Sagimet BiosciencesConference / presentation

Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a key lipid synthesis regulator, for acne, today announced that management will participate in the Guggenheim 3 rd Annual Healthcare Innovation Conference on Monday, November 9, 2026, in Boston, MA with a fireside chat at 10:30am ET (link here ).

Related news

SGMTSagimet Biosciences2026-08-04 11:00 EST

Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference

SGMTSagimet Biosciences2026-08-17 20:28 EST

Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MNKDMannKind2026-09-02 12:30 EST

MannKind to Present at Upcoming Investor Conferences

NAMSNewAmsterdam Pharma2026-07-01 12:00 EST

NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026

MNKDMannKind2026-10-14 20:01 EST

MannKind to Participate in the Chardan Healthcare Conference

ALGSAligos Therapeutics2026-10-05 20:05 EST

Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026

ALTAltimmune2026-09-03 12:00 EST

Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference

ALGSAligos Therapeutics2026-09-02 12:00 EST

Aligos Therapeutics to Present at the Cantor Global Healthcare Conference

MLYSMineralys Therapeutics2026-08-26 12:00 EST

Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

CVRXCVRx2026-07-28 12:30 EST

CVRx to Present at Canaccord Genuity's 46th Annual Growth Conference

View all latest news

Sagimet Biosciences

Metabolic Pathway Therapeutics Sagimet Biosciences develops fatty acid synthase inhibitors for diseases driven by abnormal lipid production. Denifanstat Denifanstat is an oral FASN inhibitor that reduces de novo lipogenesis and has been studied in both metabolic liver disease and dermatology. Dermatology Focus Sagimet is prioritizing...

Recent company news

SGMTSagimet Biosciences2026-10-29 11:00 EST

Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SGMTSagimet Biosciences2026-10-22 11:00 EST

Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne

SGMTSagimet Biosciences2026-10-09 11:00 EST

Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference

SGMTSagimet Biosciences2026-10-01 20:31 EST

Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants

SGMTSagimet Biosciences2026-09-30 10:19 EST

Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants

Stock data

Close
9.12 USD
Market cap
419.29M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States